Joan Pujol: una lectura contrareformista d'Ausiàs Marc

Anàlisi de l’obra del poeta Joan Pujol, concretament els textos que tenen com a referent directe la figura i/o l’obra d’Ausiàs Marc. S’ofereix una hipòtesi de lectura del conjunt de poemes presentats

La misión Méndez ante el gobierno del Dr. Juan Pujol

Fil: Luzi, Alejandra Noemí. Universidad Nacional de La Plata. Facultad de Humanidades y Ciencias de la Educación; Argentina.

La misión Méndez ante el gobierno del Dr. Juan Pujol

Fil: Luzi, Alejandra Noemí. Universidad Nacional de La Plata. Facultad de Humanidades y Ciencias de la Educación; Argentina.

Vida pública del Dr. Juan Pujol; historia de la provincia de Corrientes de marzo 1843 a diciembre 1859,

Mode of access: Internet.

Necrología del Dr. D. Joaquín Pujol y Sagristá : que, en la sesión general celebrada por el Colegio de Farmacéuticos de Barcelona, el 31 de octubre de 1860 /

Mode of access: Internet.

Pujol, chef des miquelets, ou La Catalogne, 1808-1814.

Mode of access: Internet.

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

OBJECTIVES: Four randomized phase II/III trials investigated the addition of cetuximab to platinum-based, first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). A meta-analysis was performed to examine the benefit/risk ratio for the addition of cetuximab to chemotherapy. MATERIALS AND METHODS: The meta-analysis included individual patient efficacy data from 2018 patients and individual patient safety data from 1970 patients comprising respectively the combined intention-to-treat and safety populations of the four trials. The effect of adding cetuximab to chemotherapy was measured by hazard ratios (HRs) obtained using a Cox proportional hazards model and odds ratios calculated by logistic regression. Survival rates at 1 year were calculated. All applied models were stratified by trial. Tests on heterogeneity of treatment effects across the trials and sensitivity analyses were performed for all endpoints. RESULTS: The meta-analysis demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival (HR 0.88, p=0.009, median 10.3 vs 9.4 months), progression-free survival (HR 0.90, p=0.045, median 4.7 vs 4.5 months) and response (odds ratio 1.46, p<0.001, overall response rate 32.2% vs 24.4%) compared with chemotherapy alone. The safety profile of chemotherapy plus cetuximab in the meta-analysis population was confirmed as manageable. Neither trials nor patient subgroups defined by key baseline characteristics showed significant heterogeneity for any endpoint. CONCLUSION: The addition of cetuximab to platinum-based, first-line chemotherapy for advanced NSCLC significantly improved outcome for all efficacy endpoints with an acceptable safety profile, indicating a favorable benefit/risk ratio.

Food reward sensitivity predicts overconsumption of high-fat snack food

Overconsumption of snack foods has been linked to rising rates of obesity, with our ‘obesogenic’ environment and its abundance of palatable, high-calorie foods and associated cues especially implicated. However, it is clear that some individuals are particularly susceptible to overconsumption and weight gain. It was hypothesised that individuals sensitive to the rewarding properties of palatable foods, and associated stimuli, would show elevated consumption. Snack food intake was measured in 50 adults (mean age 34.5 years, BMI 23.9 kg/m2, 56% female) in a repeated measures design, both with and without a ‘food cue’. Trait (BIS/BAS scales), behavioural (computerised CARROT) and food reward were assessed. Sensitivity to food reward, but not generalised reward, was positively associated with snack food intake. This relationship was not affected by the presence of a food cue. Findings are discussed in the context of implications for weight management.